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AUTISM-RELATED HOSPITALIZATIONS: ESTIMATES FROM 2006 HEALTH
CARE COST AND UTILIZATION PROJECT KIDS’ INPATIENT DATABASE
Khanna R, Madhavan SS
West Virginia University, Morgantown, WV, USA
OBJECTIVES: Over the past two decades, the prevalence of autism spectrum disorder
(ASD) has increased signiﬁ cantly in the United States (US). This increase in prevalence 
has been accompanied by a corresponding increase in health care utilization and costs 
associated with the disorder. The purpose of this study is to describe hospitalization
and associated costs among children with ASD in the US. METHODS: For the purpose 
of the study, the 2006 Healthcare Cost and Utilization Project (HCUP) Kids’ Inpatient
Database (KID) was used. The 2006 KID contains outcome data for ^3.1 million
discharges from 3739 community, non-rehabilitation hospitals spread across 38
states. All hospitalizations where the primary diagnosis (ICD-9-CM) code was listed
as 299.XX were categorized as autism-related. Descriptive analyses were performed
and results were reported by demographic categories. Costs associated with hospital-
izations were based on total charges. RESULTS: Of the 3,131,324 pediatric discharges 
listed in 2006 HCUP KID, 1,456 were autism-related. The total charge for these 
hospitalizations was $56,936,591. The average charge per autism-related hospitaliza-
tion was $24,042. The average age of children with autism-related hospitalization was 
12 years (o4 years), and the average length of stay was 13 days. In terms of demo-
graphic distribution, a majority of the children were white (69%) and male (82.3%). 
Medicaid was listed as the primary payer for roughly half (49%) of the discharges, 
with private payer including HMO providing for 42.9%. For approximately 57% of 
the discharges, the DRG listed was for psychoses, with another 42% for organic dis-
turbances and mental retardation. CONCLUSIONS: Autism-related hospitalizations 
result in signiﬁ cant economic impact on the society. Consistent with the prevalence 
patterns of autism, a majority of hospitalizations occurred among males. Further 
research is needed to understand the factors associated with hospitalizations among
children with ASD.
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PREDICTORS OF HIGHER HEALTH CARE EXPENDITURES IN PATIENTS
WITH ATTENTION-DEFICIT HYPERACTIVITY DISORDER
Christensen L1, Sasane R2, Hodgkins P2, Harley C3
1i3 Innovus, Ann Arbor, MI, USA, 2Shire Pharmaceuticals, Wayne, PA, USA, 3i3 Innovus, Eden
Prairie, MN, USA
OBJECTIVES: To identify risk factors associated with higher health care costs among
US commercial health plan enrollees with attention-deﬁ cit hyperactivity disorder 
(ADHD). METHODS: This retrospective study used claims data from July 1, 2003-
September 30, 2007 to examine total health care costs for subjects aged q6, diagnosed 
with ADHD, on their ﬁ rst prescription ﬁ ll (index) date for an FDA-approved ADHD
medication. Total cost (health plan plus patient paid amounts) included medical,
pharmacy, outpatient, ofﬁ ce visits, emergency and other medical costs. Subjects had
an ADHD diagnosis between January 1, 2004-September 30, 2006, and ﬁ lled q1 pre-
scription for an ADHD medication during the study period. Multivariate analysis was 
conducted for subjects with available race/ethnicity and household income data (N 
38,061). RESULTS: The highest household income group ($100,000 or more) was
associated with signiﬁ cantly higher health care cost compared with the lowest income
group ($00) (p  0.004). Follow-up costs were higher with increasing number of 
baseline medications (p  0.0001), additional mental health diagnoses (p  0.0001), 
and when the index prescriber was a neurologist, psychiatrist or internal medicine
specialist, rather than a family physician (all p  0.05). Greater medication compliance 
(MPR q 0.8) was associated with higher total costs than lower compliance (MPR 
0.8) (p  0.0001). Augmentation with a drug of another class (stimulant/nonstimulant)
and use of a nonstimulant or extended release amphetamine (vs. long-acting methyl-
phenidate) as index therapy were also associated with higher cost (all p  0.05). Costs
were not statistically different between males and females aged 6–12 but were higher
for females and males aged 13–17 and q18 than females aged 6–12 (all p  0.0001). 
Race/ethnicity was not signiﬁ cantly related to cost when controlling for demographic, 
baseline medical and treatment characteristics. CONCLUSIONS: The main predictors 
of higher health care costs for patients with ADHD were higher income, older age
and factors suggesting more complicated disease or more comorbid conditions.
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IMPACT OF THE BRAZILIAN PUBLIC MENTAL HEALTH POLICY ON
SCHIZOPHRENIA HOSPITALIZATION: A 10-YEAR ANALYSIS
Araujo GT, Fonseca MCM
UNIFESP – Federal University of Sao Paulo, Sao Paulo, Sao Paulo, Brazil
OBJECTIVES: Since the end of the 20th century, the Brazilian Health Ministry has 
been working on an effective mental health policy in order to keep patients out of the
hospital setting as much as possible. In the last 10 years, two important programs for 
the treatment of schizophrenia patients were established: In 2002 Psychosocial Atten-
tion Centers (CAPxs) and in 2003 “Back to home” program, along with the adoption
of new drugs. The purpose of this evaluation is to evaluate the impact of the Brazilian
Public Mental Health Policy on schizophrenia hospitalization reduction. METHODS:
A retrospective analysis was performed using DATASUS (Government Healthcare 
database) from Jan 1998 until Dec 2007 to investigate the number of hospitalizations
and days of hospitalization associated with schizophrenia and the cost associated to
these hospital stays. Costs are reported in Brazilian reais RESULTS: In ten years, the 
amount of hospitalizations due to schizophrenia reduced in 55% and the total costs 
associated to hospitalization reduced in 68%. The cost of one day hospitalization was
R$21.12 in 1998 and R$31, 78 in 2007. The average length of stay increased 28% 
and the average total cost of hospitalization increased 93% CONCLUSIONS: This 
analysis suggests that the mental health policy was effective in reducing schizophrenia
hospitalization rates and total costs and that the patients that are hospitalized are
probably those with more severe condition, requiring longer stay and more expensive 
health care resources.
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HOSPITALIZATION RATES AMONG INDIVIDUALS WITH BIPOLAR
DISORDER INITIATING THERAPY WITH ARIPIPRAZOLE OR QUETIAPINE
Hassan M1, Lage MJ2
1AstraZeneca, Wilmington, DE, USA, 2HealthMetrics Outcomes Research, LLC, Groton, CT, 
USA
OBJECTIVES: Changes in rates of hospitalization were compared for patients with 
bipolar disorder initiating treatment with aripiprazole (ARI) or quetiapine (QTP). 
METHODS: Claims data for patients diagnosed with bipolar disorder from a com-
mercial managed care database (PharMetrics January 1, 2000–December 31, 2006) 
were examined (N  2573). Patients were aged 18 to 64 years, initiated therapy with
ARI or QTP, prescribed no other antipsychotic in the ﬁ rst month post-initiation, had
no dementia or schizophrenia diagnoses, and were continuously insured from 12 
months prior through 12 months post-initiation. Patient characteristics were com-
pared between groups using descriptive statistics. Rates of hospitalization for any
cause or related to mental health or bipolar disorder, from 12 months before to 12
months after treatment initiation, were compared between groups using McNemar’s 
test. RESULTS: Approximately 75% of patients were initiated on QTP and 25% on
ARI. During the pre-initiation period, treatment groups were not signiﬁ cantly different
in terms of age, gender, or Charlson Comorbidity score, but the QTP group had a 
greater total number of ICD-9 coded medical diagnoses than patients in the ARI group
(mean 13.11 [QTP] vs 11.06 [ARI]; P  0.0001). Initiation with QTP, compared with
ARI, was associated with a signiﬁ cantly longer time before discontinuation (mean
197.30 days [QTP] vs 175.84 days [ARI], P  0.0009). When comparing rates of 
hospitalization due to any cause, the QTP group showed a signiﬁ cant reduction post-
initiation versus pre-initiation, while the ARI group showed a signiﬁ cant increase
post-initiation (2.89% [QTP] vs 0.47% [ARI], P  0.0001). The QTP group also 
showed reduced rates of mental health- and bipolar disorder-related hospitalizations, 
while the ARI group showed increased rates (3.35% [QTP] vs 1.10% [ARI]; P 
0.0004; 0.57% [QTP] vs 3.79% [ARI], P  0.0128). CONCLUSIONS: Decreased 
rates of hospitalization were observed among patients with bipolar disorder after
initiation on QTP compared with ARI. Supported by funding from AstraZeneca 
Pharmaceuticals LP.
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OBJECTIVES: Many patients with depression are not responsive to ﬁ rst-line treatment
and undergo treatment switches and optimizations to discover a beneﬁ cial regimen 
(‘treatment-resistant’ depression [TRD]). In addition to the patient burden, TRD is 
associated with signiﬁ cant economic costs. Challenges in treating patients with TRD 
are further complicated by the lack of a recognized deﬁ nition of TRD. Using admin-
istrative data, we compare three claims-based methods (developed by Corey-Lisle, 
Crown and Russell) and a clinically-derived measure (MGH scale) of ﬁ nding patients
with TRD. METHODS: A retrospective study of patients aged 18–64 years with at
least one antidepressant claim and employer-based coverage via large US ﬁ rms.
Patients had at least 2 years of continuous medical and prescription coverage in the 
MarketScan Database for 2000–2006 (n  106,139). TRD classiﬁ cation methods were 
replicated over a 24-month observation period. Kappa coefﬁ cients were used to assess 
agreement between dichotomous TRD measures. The relationship between continuous 
measures of TRD (based on the number of antidepressant switches and optimizations,
and other metrics) and annual medical costs were also assessed. RESULTS: Over two 
thirds of patients (69.6%, n  73,872) were classiﬁ ed in a similar manner across all 
four methods: 10.7 % of patients (n  11,349) were found to have TRD, and the
majority of patients (58.9%, n  62,515) did not have TRD. However, 30.4% of 
patients (n  32,252) were classiﬁ ed differently depending on the method. Kappa
coefﬁ cients between pairs of methods ranged from 0.85% to 0.42%. As TRD severity
increased, cost increased in an almost linear fashion. CONCLUSIONS: While patients 
with complex TRD are relatively easy to identify in health care administrative data, 
those with less complex TRD represent an opportunity for earlier recognition and 
intervention and associated potential cost savings. Dichotomous deﬁ nitions of TRD 
may not be adequate; a gradient from moderate to complex TRD may be more useful 
for providers and insurers.
